Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/378
| Subject | Predicate | Object | Context |
|---|---|---|---|
| dailymed-drugs:378 | rdf:type | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:378 | rdf:type | dailymed-instance:drugs | lld:dailymed |
| dailymed-drugs:378 | rdfs:label | Dextrose in Lactated Ringer's (Injection) | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:dosage | General Instructions: Fluorouracil Injection, USP should be administered only intravenously, using care to avoid extravasation. No dilution is required. All dosages are based on the patient's actual weight. However, the estimated lean body mass (dry weight) is used if the patient is obese or if there has been a spurious weight gain due to edema, ascites or other forms of abnormal fluid retention. It is recommended that prior to treatment each patient be carefully evaluated in order to estimate as accurately as possible the optimum initial dosage of Fluorouracil.<br/>Dosage: 12 mg/kg are given intravenously once daily for 4 successive days. The daily dose should not exceed 800 mg. If no toxicity is observed, 6 mg/kg are given on the 6, 8, 10and 12days unless toxicity occurs. No therapy is given on the 5, 7, 9or 11days. Therapy is to be discontinued at the end of the 12day, even if no toxicity has become apparent. (See WARNINGS and PRECAUTIONS sections.) Poor risk patients or those who are not in an adequate nutritional state (see CONTRAINDICATIONS and WARNINGS sections) should receive 6 mg/kg/day for 3 days. If no toxicity is observed, 3 mg/kg may be given on the 5, 7and 9days unless toxicity occurs. No therapy is given on the 4, 6or 8days. The daily dose should not exceed 400 mg. A sequence of injections on either schedule constitutes a"course of therapy."<br/>Maintenance Therapy: In instances where toxicity has not been a problem, it is recommended that therapy be continued using either of the following schedules: The patient's reaction to the previous course of therapy should be taken into account in determining the amount of the drug to be used, and the dosage should be adjusted accordingly. Some patients have received from 9 to 45 courses of treatment during periods which ranged from 12 to 60 months.<br/>Handling and Disposal: Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate. Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Although the Fluorouracil solution may discolor slightly during storage, the potency and safety are not adversely affected. If a precipitate occurs due to exposure to lowtemperatures, resolubilize by heating to 140��F and shaking vigorously; allow to cool to body temperature before using. | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:descripti... | Fluorouracil Injection, USP an antineoplastic antimetabolite, is a sterile, nonpyrogenic injectable solution for intravenous administration. Each mL contains 50 mg of fluorouracil and water for injection. Sodium hydroxide may be added to adjust pH to approximately 9.2 during manufacture. Chemically, fluorouracil, a fluorinated pyrimidine, is 5-fluoro-2,4 (1H,3H)-pyrimidinedione. It is a white to practically white crystalline powder which is sparingly soluble in water. The molecular weight of fluorouracil is 130.08. Molecular formula of fluorouracil is: CHFNO. The structural formula is: | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:clinicalP... | There is evidence that the metabolism of fluorouracil in the anabolic pathway blocks the methylation reaction of deoxyuridylic acid to thymidylic acid. In this manner, fluorouracil interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA). Since DNA and RNA are essential for cell division and growth, the effect of fluorouracil may be to create a thymine deficiency which provokes unbalanced growth and death of the cell. The effects of DNA and RNA deprivation are most marked on those cells which grow more rapidly and which take up fluorouracil at a more rapid rate. Following intravenous injection, fluorouracil distributes into tumors, intestinal mucosa, bone marrow, liver and other tissues throughout the body. In spite of its limited lipid solubility, fluorouracil diffuses readily across the blood-brain barrier and distributes into cerebrospinal fluid and brain tissue. Seven percent to 20% of the parent drug is excreted unchanged in the urine in 6 hours; of this over 90% is excreted in the first hour. The remaining percentage of the administered dose is metabolized, primarily in the liver. The catabolic metabolism of fluorouracil results in degradation products (e.g., CO, urea and��-fluoro-��-alanine) which are inactive. The inactive metabolites are excreted in the urine over the next 3 to 4 hours. When fluorouracil is labeled in the six carbon position, thus preventing theC metabolism to CO, approximately 90% of the total radioactivity is excreted in the urine. When fluorouracil is labeled in the two carbon position approximately 90% of the total radioactivity is excreted in expired CO. Ninety percent of the dose is accounted for during the first 24 hours following intravenous administration. Following intravenous administration of fluorouracil, the mean half-life of elimination from plasma is approximately 16 minutes, with a range of 8 to 20 minutes, and is dose dependent. No intact drug can be detected in the plasma 3 hours after an intravenous injection. | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:contraind... | Fluorouracil therapy is contraindicated for patients in a poor nutritional state, those with depressed bone marrow function, those with potentially serious infections or those with a known hypersensitivity to Fluorouracil. | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:supply | Fluorouracil Injection, USP is available for intravenouse use in 10 mL vials. Each mL contains 50 mg (available as 500 mg/10 mL) of fluorouracil in a colorless to faint yellow aqueous solution. Sodium hydroxide may have been added to adjust the pH to approximately 9.2 during manufacture. NDC 66758-044-01: 10 mL single use vials<br/>STORAGE: Store at 20��to 25��C (68��to 77��F) [See USP Controlled Room Temperature]. Do not refrigerate or freeze. Protect from light. Retain in carton until contents are used. Discard any unused portion. For Parenta Customer Service, call 1-800-898-9948. | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:genericDr... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:boxedWarn... | WARNING: It is recommended that Fluorouracil Injection be given only by or under the supervision of a qualified physician who is experienced in cancer chemotherapy and who is well versed in the use of potent antimetabolites. Because of the possibility of severe toxic reactions, it is recommended that patients be hospitalized at least during the initial course of therapy. These instructions should be thoroughly reviewed before administration of Fluorouracil Injection, USP. | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:possibleD... | diseasome-diseases:409 | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:possibleD... | diseasome-diseases:1131 | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:possibleD... | diseasome-diseases:2398 | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:possibleD... | diseasome-diseases:4051 | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:overdosag... | The possibility of overdosage with fluorouracil is unlikely in view of the mode of administration. Nevertheless, the anticipated manifestations would be nausea, vomiting, diarrhea, gastrointestinal ulceration and bleeding, bone marrow depression (including thrombocytopenia, leukopenia and agranulocytosis). No specific antidotal therapy exists. Patients who have been exposed to an overdose of fluorouracil should be monitored hematologically for at least four weeks. Should abnormalities appear, appropriate therapy should be utilized. The acute intravenous toxicity of fluorouracil is as follows: | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:genericMe... | Fluorouracil | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:fullName | Dextrose in Lactated Ringer's (Injection) | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:adverseRe... | Stomatitis and esophagopharyngitis (which may lead to sloughing and ulceration), diarrhea, anorexia, nausea and emesis are commonly seen during therapy. Leukopenia usually follows every course of adequate therapy with fluorouracil. The lowest white blood cell counts are commonly observed between the 9and 14days after the first course of treatment, although uncommonly the maximal depression may be delayed for as long as 20 days. By the 30day the count has usually returned to the normal range. Alopecia and dermatitis may be seen in a substantial number of cases. The dermatitis most often seen is a pruritic maculopapular rash usually appearing on the extremities and less frequently on the trunk. It is generally reversible and usually responsive to symptomatic treatment. Other adverse reactions are: Hematologic: pancytopenia, thrombocytopenia, agranulocytosis, anemia. Cardiovascular: myocardial ischemia, angina. Gastrointestinal: gastrointestinal ulceration and bleeding. Allergic Reactions: anaphylaxis and generalized allergic reactions. Neurologic: acute cerebellar syndrome (which may persist following discontinuance of treatment), nystagmus, headache. Dermatologic: dry skin; fissuring; photosensitivity, as manifested by erythema or increased pigmentation of the skin; vein pigmentation; palmar-plantar erythrodysesthesia syndrome, as manifested by tingling of the hands and feet followed by pain, erythema and swelling. Ophthalmic: lacrimal duct stenosis, visual changes, lacrimation, photophobia. Psychiatric: disorientation, confusion, euphoria. Miscellaneous: thrombophlebitis, epistaxis, nail changes (including loss of nails). | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:indicatio... | Fluorouracil Injection, USP is effective in the palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas. | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:routeOfAd... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:378 | dailymed-instance:name | Dextrose in Lactated Ringer's | lld:dailymed |
| diseasome-diseases:409 | diseasome-instance:possible... | dailymed-drugs:378 | lld:diseasome |
| diseasome-diseases:1131 | diseasome-instance:possible... | dailymed-drugs:378 | lld:diseasome |
| diseasome-diseases:2398 | diseasome-instance:possible... | dailymed-drugs:378 | lld:diseasome |
| diseasome-diseases:4051 | diseasome-instance:possible... | dailymed-drugs:378 | lld:diseasome |